Evaluate Vantage Homepage
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
The developer has now struck two rich deals for the antibiotics space, a field that infrequently sees big sums change hands.
Neither project is an obvious candidate for phase 3, so more mid-stage trials are planned.
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
It is make or break time for the smaller group’s TL1A inhibitor PRA023.
Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.
An unusual update at last month’s AAIC meeting puts the focus on a phase 2 readout next year, but time might be running out.
Before the Forma deal Novo brought in assets via Corvidia, Prothena and Heartseed. Some have progressed faster than others.